Drug repurposing is the application of approved drugs to treat diseases separate and distinct from their original indications. Herein, we define the scope of all practical precision drug repurposing using DrugBank, a publicly available database of pharmacological agents, and BioVU, a large, de-identified DNA repository linked to longitudinal electronic health records at Vanderbilt University Medical Center. We present a method of repurposing candidate prioritization through integration of pharmacodynamic and marketing variables from DrugBank with quality control thresholds for genomic data derived from the DNA samples within BioVU. Through the synergy of delineated "target-action pairs," along with target genomics, we identify ∼230 "pairs" that represent all practical opportunities for genomic drug repurposing. From this analysis, we present a pipeline of 14 repurposing candidates across 7 disease areas that link to our repurposability platform and present high potential for randomized controlled trial startup in upcoming months.

中文翻译：

---

在基于基因组的药物再利用中系统地优先考虑候选药物。

药物再利用是指将已批准的药物应用于治疗与其原始适应症不同的疾病。在此，我们使用 DrugBank（一个公开的药物制剂数据库）和 BioVU（一个与范德比尔特大学医学中心的纵向电子健康记录相关的大型去识别化 DNA 存储库）定义了所有实用精准药物再利用的范围。我们提出了一种通过整合 DrugBank 中的药效学和营销变量与 BioVU 内 DNA 样本的基因组数据的质量控制阈值来重新确定候选者优先顺序的方法。通过所描述的“目标-作用对”与目标基因组学的协同作用，我们确定了约 230 个“对”，它们代表了基因组药物再利用的所有实际机会。根据这项分析，我们提出了涵盖 7 个疾病领域的 14 个再利用候选药物的管道，这些候选者与我们的再利用平台相关联，并在未来几个月内启动随机对照试验具有很高的潜力。